PR002674 (Project)

Description:This project aims to develop and validate a blood-based biomarker model to identify individuals at elevated risk of asthma exacerbations. Global metabolomics highlighted steroid, sphingolipid, and microbiome-linked metabolic pathways as associated with asthma status and exacerbation risk. Targeted quantification showed that sphingolipid-to-steroid ratios were strongly and consistently associated with 5‑year risk of exacerbation. Derived a simple predictive model based on 21 sphingolipid-to-steroid ratios that replicated across cohorts and outperformed current clinical measures (discovery AUC = 0.90; replication AUC = 0.89). These findings underscore the value of metabolomic profiling to develop a practical, cost-effective clinical assay for asthma exacerbation risk that may improve patient care.